Tyra Biosciences, Inc. (TYRA)

$10.37

+1.35 (+14.97%)
Rating:
Recommendation:
-
Symbol TYRA
Price $10.37
Beta 0.000
Volume Avg. 0.06M
Market Cap 435.266M
Shares () -
52 Week Range 4.93-31.36
1y Target Est -
DCF Unlevered TYRA DCF ->
DCF Levered TYRA LDCF ->
ROE -9.34% Neutral
ROA -7.06% Neutral
Operating Margin -
Debt / Equity 2.96% Neutral
P/E -
P/B 1.55 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades


Healthcare
Biotechnology
NASDAQ Global Select

Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The company is also developing programs targeting FGFR2- intrahepatic cholangiocarcinoma,FGFR3-related achondroplasia, REarranged during transfection kinase, and FGFR4-related cancers. In addition, the company offers SNAP platform which enable rapid structural design through iterative molecular SNAPshots. Tyra Biosciences, Inc. was incorporated in 2018 and is based in Carlsbad, California.